The increasing prevalence of newborn genetic screening has led to earlier DMD diagnoses, with more and more patients being diagnosed prior to the development of symptoms. However, minimal clinical guidance […]
TREAT-NMD news
New AAN Evidence in Focus Article Highlights Gene Therapy for Duchenne Muscular Dystrophy
The American Academy of Neurology (AAN) has recently published a new Evidence in Focus article that may be of particular interest to the TREAT-NMD network. The piece, titled “Delandistrogene Moxeparvovec [...]
TREAT-NMD Announces Dr. Kathryn R. Wagner as New Chair of the Board
20 May 2025 – TREAT-NMD, a global network dedicated to accelerating treatments for neuromuscular diseases, is pleased to announce the appointment of Kathryn R. Wagner, MD, PhD, as its new […]
Project PaLaDIn
TREAT-NMD is the scientific coordinator of the IHI funded project PaLaDIn. The PaLaDIn consortium includes partners from SMEs, academia and patient advocacy organisations, working together to develop and implement a […]
We are pleased to announce the release of Version 1.0 of the TREAT-NMD Standard Neuromuscular Disease (sNMD) Dataset
The idea for the Standard Neuromuscular Disease (sNMD) dataset originated from the TREAT-NMD Ultra-Rare Subgroup (now known as the sNMD subgroup), led at the time by Robin Forbes (Australian Neuromuscular Disease Registry) […]
8th TREAT-NMD® International Conference – Lisbon, 2026!
TREAT-NMD® is internationally recognised for our key role in successfully addressing some of the major issues that face therapeutic development in neuromuscular diseases. We connect the global neuromuscular community, inform […]
